Impact of pramipexole on the onset of levodopa‐related dyskinesias
Identifieur interne : 003742 ( Istex/Corpus ); précédent : 003741; suivant : 003743Impact of pramipexole on the onset of levodopa‐related dyskinesias
Auteurs : Radu Constantinescu ; Megan Romer ; Michael P. Mcdermott ; Cornelia Kamp ; Karl KieburtzSource :
- Movement Disorders [ 0885-3185 ] ; 2007-07-15.
English descriptors
Abstract
Dyskinesias are a major complication of dopaminergic therapy in the long‐term treatment of Parkinson's disease. In the CALM‐PD trial, subjects were initially randomized to levodopa or pramipexole and could later add levodopa if needed. After adjusting for disease duration and daily levodopa dosage, the incidence of dyskinesias after initiating levodopa was not significantly different among subjects initially randomized to levodopa and those initially randomized to pramipexole. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21292
Links to Exploration step
ISTEX:B0896B7AACAB7F89FDC7897DCC5BD214C3C4D1C5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of pramipexole on the onset of levodopa‐related dyskinesias</title><author><name sortKey="Constantinescu, Radu" sort="Constantinescu, Radu" uniqKey="Constantinescu R" first="Radu" last="Constantinescu">Radu Constantinescu</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Romer, Megan" sort="Romer, Megan" uniqKey="Romer M" first="Megan" last="Romer">Megan Romer</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Kamp, Cornelia" sort="Kamp, Cornelia" uniqKey="Kamp C" first="Cornelia" last="Kamp">Cornelia Kamp</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B0896B7AACAB7F89FDC7897DCC5BD214C3C4D1C5</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21292</idno><idno type="url">https://api.istex.fr/document/B0896B7AACAB7F89FDC7897DCC5BD214C3C4D1C5/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003742</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Impact of pramipexole on the onset of levodopa‐related dyskinesias</title><author><name sortKey="Constantinescu, Radu" sort="Constantinescu, Radu" uniqKey="Constantinescu R" first="Radu" last="Constantinescu">Radu Constantinescu</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Romer, Megan" sort="Romer, Megan" uniqKey="Romer M" first="Megan" last="Romer">Megan Romer</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Kamp, Cornelia" sort="Kamp, Cornelia" uniqKey="Kamp C" first="Cornelia" last="Kamp">Cornelia Kamp</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-07-15">2007-07-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1317">1317</biblScope><biblScope unit="page" to="1319">1319</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">B0896B7AACAB7F89FDC7897DCC5BD214C3C4D1C5</idno><idno type="DOI">10.1002/mds.21292</idno><idno type="ArticleID">MDS21292</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dopamine agonists</term><term>dyskinesias</term><term>levodopa</term><term>pramipexole</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dyskinesias are a major complication of dopaminergic therapy in the long‐term treatment of Parkinson's disease. In the CALM‐PD trial, subjects were initially randomized to levodopa or pramipexole and could later add levodopa if needed. After adjusting for disease duration and daily levodopa dosage, the incidence of dyskinesias after initiating levodopa was not significantly different among subjects initially randomized to levodopa and those initially randomized to pramipexole. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Radu Constantinescu MD</name><affiliations><json:string>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Megan Romer MS</name><affiliations><json:string>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Michael P. McDermott PhD</name><affiliations><json:string>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</json:string><json:string>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Cornelia Kamp MBA</name><affiliations><json:string>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Karl Kieburtz MD, MPH</name><affiliations><json:string>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dyskinesias</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pramipexole</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine agonists</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Dyskinesias are a major complication of dopaminergic therapy in the long‐term treatment of Parkinson's disease. In the CALM‐PD trial, subjects were initially randomized to levodopa or pramipexole and could later add levodopa if needed. After adjusting for disease duration and daily levodopa dosage, the incidence of dyskinesias after initiating levodopa was not significantly different among subjects initially randomized to levodopa and those initially randomized to pramipexole. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>2.781</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>514</abstractCharCount><pdfWordCount>1929</pdfWordCount><pdfCharCount>12438</pdfCharCount><pdfPageCount>3</pdfPageCount><abstractWordCount>71</abstractWordCount></qualityIndicators><title>Impact of pramipexole on the onset of levodopa‐related dyskinesias</title><genre><json:string>Serial article</json:string></genre><host><volume>22</volume><pages><total>3</total><last>1319</last><first>1317</first></pages><issn><json:string>0885-3185</json:string></issn><issue>9</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21292</json:string></doi><id>B0896B7AACAB7F89FDC7897DCC5BD214C3C4D1C5</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/B0896B7AACAB7F89FDC7897DCC5BD214C3C4D1C5/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/B0896B7AACAB7F89FDC7897DCC5BD214C3C4D1C5/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/B0896B7AACAB7F89FDC7897DCC5BD214C3C4D1C5/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Impact of pramipexole on the onset of levodopa‐related dyskinesias</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2007</date></publicationStmt><notesStmt><note>Boehringer Ingelheim and the Parkinson Disease Foundation</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Impact of pramipexole on the onset of levodopa‐related dyskinesias</title><author><persName><forename type="first">Radu</forename><surname>Constantinescu</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Neurologkliniken, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden</p></note><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Megan</forename><surname>Romer</surname><roleName type="degree">MS</roleName></persName><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Michael P.</forename><surname>McDermott</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation><affiliation>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Cornelia</forename><surname>Kamp</surname><roleName type="degree">MBA</roleName></persName><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Karl</forename><surname>Kieburtz</surname><roleName type="degree">MD, MPH</roleName></persName><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-07-15"></date><biblScope unit="vol">22</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1317">1317</biblScope><biblScope unit="page" to="1319">1319</biblScope></imprint></monogr><idno type="istex">B0896B7AACAB7F89FDC7897DCC5BD214C3C4D1C5</idno><idno type="DOI">10.1002/mds.21292</idno><idno type="ArticleID">MDS21292</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Dyskinesias are a major complication of dopaminergic therapy in the long‐term treatment of Parkinson's disease. In the CALM‐PD trial, subjects were initially randomized to levodopa or pramipexole and could later add levodopa if needed. After adjusting for disease duration and daily levodopa dosage, the incidence of dyskinesias after initiating levodopa was not significantly different among subjects initially randomized to levodopa and those initially randomized to pramipexole. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>dyskinesias</term></item><item><term>pramipexole</term></item><item><term>levodopa</term></item><item><term>dopamine agonists</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-04-21">Received</change><change when="2006-09-14">Registration</change><change when="2007-07-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/B0896B7AACAB7F89FDC7897DCC5BD214C3C4D1C5/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="90"><doi origin="wiley" registered="yes">10.1002/mds.v22:9</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">9</numbering></numberingGroup><coverDate startDate="2007-07-15">15 July 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="170" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21292</doi><idGroup><id type="unit" value="MDS21292"></id></idGroup><countGroup><count type="pageTotal" number="3"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2006-04-21"></event><event type="manuscriptRevised" date="2006-09-01"></event><event type="manuscriptAccepted" date="2006-09-14"></event><event type="publishedOnlineEarlyUnpaginated" date="2007-05-29"></event><event type="firstOnline" date="2007-05-29"></event><event type="publishedOnlineFinalForm" date="2007-07-23"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1317</numbering><numbering type="pageLast">1319</numbering></numberingGroup><correspondenceTo>Neurologkliniken, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21292.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="14"></count><count type="wordTotal" number="2181"></count></countGroup><titleGroup><title type="main" xml:lang="en">Impact of pramipexole on the onset of levodopa‐related dyskinesias</title><title type="short" xml:lang="en">Impact of Pramipexole</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Radu</givenNames><familyName>Constantinescu</familyName><degrees>MD</degrees></personName><contactDetails><email>radu.constantinescu@vgregion.se</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Megan</givenNames><familyName>Romer</familyName><degrees>MS</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Michael P.</givenNames><familyName>McDermott</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Cornelia</givenNames><familyName>Kamp</familyName><degrees>MBA</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Karl</givenNames><familyName>Kieburtz</familyName><degrees>MD, MPH</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">dyskinesias</keyword><keyword xml:id="kwd3">pramipexole</keyword><keyword xml:id="kwd4">levodopa</keyword><keyword xml:id="kwd5">dopamine agonists</keyword></keywordGroup><fundingInfo><fundingAgency>Boehringer Ingelheim and the Parkinson Disease Foundation</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Dyskinesias are a major complication of dopaminergic therapy in the long‐term treatment of Parkinson's disease. In the CALM‐PD trial, subjects were initially randomized to levodopa or pramipexole and could later add levodopa if needed. After adjusting for disease duration and daily levodopa dosage, the incidence of dyskinesias after initiating levodopa was not significantly different among subjects initially randomized to levodopa and those initially randomized to pramipexole. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Impact of pramipexole on the onset of levodopa‐related dyskinesias</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Impact of Pramipexole</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Impact of pramipexole on the onset of levodopa‐related dyskinesias</title></titleInfo><name type="personal"><namePart type="given">Radu</namePart><namePart type="family">Constantinescu</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation><description>Correspondence: Neurologkliniken, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Megan</namePart><namePart type="family">Romer</namePart><namePart type="termsOfAddress">MS</namePart><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael P.</namePart><namePart type="family">McDermott</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation><affiliation>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cornelia</namePart><namePart type="family">Kamp</namePart><namePart type="termsOfAddress">MBA</namePart><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karl</namePart><namePart type="family">Kieburtz</namePart><namePart type="termsOfAddress">MD, MPH</namePart><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-07-15</dateIssued><dateCaptured encoding="w3cdtf">2006-04-21</dateCaptured><dateValid encoding="w3cdtf">2006-09-14</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">14</extent><extent unit="words">2181</extent></physicalDescription><abstract lang="en">Dyskinesias are a major complication of dopaminergic therapy in the long‐term treatment of Parkinson's disease. In the CALM‐PD trial, subjects were initially randomized to levodopa or pramipexole and could later add levodopa if needed. After adjusting for disease duration and daily levodopa dosage, the incidence of dyskinesias after initiating levodopa was not significantly different among subjects initially randomized to levodopa and those initially randomized to pramipexole. © 2007 Movement Disorder Society</abstract><note type="funding">Boehringer Ingelheim and the Parkinson Disease Foundation</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>dyskinesias</topic><topic>pramipexole</topic><topic>levodopa</topic><topic>dopamine agonists</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>1317</start><end>1319</end><total>3</total></extent></part></relatedItem><identifier type="istex">B0896B7AACAB7F89FDC7897DCC5BD214C3C4D1C5</identifier><identifier type="DOI">10.1002/mds.21292</identifier><identifier type="ArticleID">MDS21292</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003742 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003742 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:B0896B7AACAB7F89FDC7897DCC5BD214C3C4D1C5
|texte= Impact of pramipexole on the onset of levodopa‐related dyskinesias
}}
| This area was generated with Dilib version V0.6.23. |  |